{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T18:17:18Z","timestamp":1791051438918,"version":"4.1.0"},"reference-count":81,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T00:00:00Z","timestamp":1559174400000},"content-version":"vor","delay-in-days":879,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Hepatology"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.5604\/16652681.1226814","type":"journal-article","created":{"date-parts":[[2016,12,23]],"date-time":"2016-12-23T05:23:47Z","timestamp":1482470627000},"page":"48-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":169,"title":["Management Strategies for Liver Fibrosis"],"prefix":"10.1016","volume":"16","author":[{"given":"Alejandra","family":"Altamirano-Barrera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Barranco-Fragoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahum","family":"M\u00e9ndez-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.5604\/16652681.1226814_bib0005","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1002\/hep.28677","article-title":"Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: The multiethnic cohort","volume":"64","author":"Setiawan","year":"2016","journal-title":"Hepatology"},{"key":"10.5604\/16652681.1226814_bib0010","series-title":"Ann Hepatol","first-page":"52","article-title":"Trends in liver disease prevalence in Mexico from 2005 to 2050 through mortality data","author":"M\u00e9ndez-S\u00e1nchez","year":"2005"},{"key":"10.5604\/16652681.1226814_bib0015","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S1665-2681(19)32122-2","article-title":"Etiology of liver cirrhosis in Mexico","volume":"3","author":"M\u00e9ndez-S\u00e1nchez","year":"2004","journal-title":"Annals of Hepatology"},{"key":"10.5604\/16652681.1226814_bib0020","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000317248","article-title":"Liver cirrhosis mortality in Europe, with special attention to Central and Eastern Europe","volume":"16","author":"Zatonski","year":"2010","journal-title":"Eur Addict Res"},{"key":"10.5604\/16652681.1226814_bib0025","doi-asserted-by":"crossref","first-page":"4850","DOI":"10.2174\/092986712803341520","article-title":"Role of oxidative stress and molecular changes in liver fibrosis: a review","volume":"19","author":"S\u00e1nchez-Valle","year":"2012","journal-title":"Curr Med Chem"},{"key":"10.5604\/16652681.1226814_bib0030","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1136\/gutjnl-2014-306842","article-title":"Pathobiology of liver fi-brosis: a translational success story","volume":"64","author":"Lee","year":"2015","journal-title":"Gut"},{"key":"10.5604\/16652681.1226814_bib0035","doi-asserted-by":"crossref","first-page":"e87336","DOI":"10.1172\/jci.insight.87336","article-title":"Hybrid inhibitor of peripheral cannabinoid-1 receptors and inducible nitric oxide synthase mitigates liver fibrosis","volume":"1","author":"Cinar","year":"2016","journal-title":"JCI Insight"},{"key":"10.5604\/16652681.1226814_bib0040","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1586\/17474124.2.6.803","article-title":"Advances in antifibrotic therapy","volume":"2","author":"Ghiassi-Nejad","year":"2008","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.5604\/16652681.1226814_bib0045","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet"},{"key":"10.5604\/16652681.1226814_bib0050","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/hep.25606","article-title":"A morphometric and immunohis-tochemical study to assess the benefit of a sustained viro-logical response in hepatitis C virus patients with cirrhosis","volume":"56","author":"D\u2019Ambrosio","year":"2012","journal-title":"Hepatology"},{"key":"10.5604\/16652681.1226814_bib0055","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jhep.2004.01.009","article-title":"Decreased fibrosis during corticos-teroid therapy of autoimmune hepatitis","volume":"40","author":"Czaja","year":"2004","journal-title":"J Hepatol"},{"key":"10.5604\/16652681.1226814_bib0060","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1007\/s10620-016-4254-7","article-title":"Targeting Hepatic Fibrosis in Autoimmune Hepatitis","volume":"61","author":"Montano-Loza","year":"2016","journal-title":"Dig Dis Sci"},{"key":"10.5604\/16652681.1226814_bib0065","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/hep.23279","article-title":"Increased caffeine consumption is associated with reduced hepatic fibrosis","volume":"51","author":"Modi","year":"2010","journal-title":"Hepatology"},{"key":"10.5604\/16652681.1226814_bib0070","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1053\/j.gastro.2004.09.075","article-title":"Coffee and caffeine consumption reduce the risk of elevated serum alanine aminotransferase activity in the United States","volume":"128","author":"Ruhl","year":"2005","journal-title":"Gastroenterology"},{"key":"10.5604\/16652681.1226814_bib0075","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/sj.bjp.0706812","article-title":"Adenosine A (2A) receptors play a role in the pathogenesis of hepatic cirrhosis","volume":"148","author":"Chan","year":"2006","journal-title":"Br J Pharmacol"},{"key":"10.5604\/16652681.1226814_bib0080","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S1665-2681(19)30931-7","article-title":"High coffee intake is associated with lower grade nonalcoholic fatty liver disease: the role of peripheral antioxidant activity","volume":"11","author":"Guti\u00e9rrez-Grobe","year":"2012","journal-title":"Ann Hepatol"},{"key":"10.5604\/16652681.1226814_bib0085","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S1665-2681(19)31949-0","article-title":"Biliary secretion and excretion in health and disease: current concepts","volume":"6","author":"Hofmann","year":"2007","journal-title":"Ann Hepatol"},{"key":"10.5604\/16652681.1226814_bib0090","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/hep.510290301","article-title":"Long-term ursodeoxycholic acid delays histo-logical progression in primary biliary cirrhosis","volume":"29","author":"Angulo","year":"1999","journal-title":"Hepatology"},{"key":"10.5604\/16652681.1226814_bib0095","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1053\/jhep.2000.20240","article-title":"The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis","volume":"32","author":"Corpechot","year":"2000","journal-title":"Hepatology"},{"key":"10.5604\/16652681.1226814_bib0100","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.3748\/wjg.14.1108","article-title":"Ursodeoxycholic acid treatment improves hepatocyte ultrastructure in rat liver fibrosis","volume":"14","author":"Mas","year":"2008","journal-title":"World J Gastroenterol"},{"key":"10.5604\/16652681.1226814_bib0105","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1023\/A:1005615306596","article-title":"Ursodeoxycholic acid suppresses extent of lipid peroxidation in diseased liver in experimental cholestatic liver disease","volume":"45","author":"Ljubuncic","year":"2000","journal-title":"Dig Dis Sci"},{"key":"10.5604\/16652681.1226814_bib0110","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.cgh.2007.07.015","article-title":"Transplantation trends in primary biliary cirrhosis","volume":"5","author":"Lee","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.5604\/16652681.1226814_bib0115","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0016-5085(86)90457-9","article-title":"Differing effect of norursodeoxy-cholic and ursodeoxycholic acid on hepatic histology and bile acid metabolism in rabbit","volume":"91","author":"Cohen","year":"1986","journal-title":"Gastroenterology"},{"key":"10.5604\/16652681.1226814_bib0120","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1665-2681(19)32071-X","article-title":"Transcriptional regulation of hepatobil-iary transport systems in health and disease: implications for a rationale approach to the treatment of intrahepatic cholestasis","volume":"4","author":"Wagner","year":"2005","journal-title":"Ann Hepatol"},{"key":"10.5604\/16652681.1226814_bib0125","first-page":"5","article-title":"Recent advances in understanding and managing cholestasis","volume":"19","author":"Wagner","year":"2016","journal-title":"F1000 Res"},{"key":"10.5604\/16652681.1226814_bib0130","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1053\/j.gastro.2005.10.055","article-title":"Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners","volume":"130","author":"Radaeva","year":"2006","journal-title":"Gastroenterology"},{"key":"10.5604\/16652681.1226814_bib0135","first-page":"890","article-title":"Interferon alfa down-regulates collagen gene transcription and suppresses experimental hepatic fi-brosis in mice","volume":"38","author":"Inagaki","year":"2003","journal-title":"Hepatology"},{"key":"10.5604\/16652681.1226814_bib0140","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1053\/j.gastro.2007.09.034","article-title":"Abrogation of the antifibrotic effects of natural killer cells\/interferon-gamma contributes to alcohol acceleration of liver fibrosis","volume":"134","author":"Jeong","year":"2008","journal-title":"Gastroenterology"},{"key":"10.5604\/16652681.1226814_bib0145","doi-asserted-by":"crossref","first-page":"G628","DOI":"10.1152\/ajpgi.00137.2006","article-title":"Beneficial effect of glatiramer acetate (Co-paxone) on immune modulation of experimental hepatic fibro-sis","volume":"292","author":"Horani","year":"2007","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.5604\/16652681.1226814_bib0150","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1136\/gut.2010.211136","article-title":"Amelioration of hepatic fibrosis by NK cell activation","volume":"60","author":"Muhanna","year":"2011","journal-title":"Gut"},{"key":"10.5604\/16652681.1226814_bib0155","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.febslet.2007.11.015","article-title":"FXR signaling in metabolic disease","volume":"582","author":"Zhang","year":"2008","journal-title":"FEBS Lett"},{"key":"10.5604\/16652681.1226814_bib0160","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1053\/j.gastro.2004.08.001","article-title":"The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis","volume":"127","author":"Fiorucci","year":"2004","journal-title":"Gastroenterology"},{"key":"10.5604\/16652681.1226814_bib0165","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1053\/j.gastro.2013.05.042","article-title":"Efficacy and safety of the far-nesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease","volume":"145","author":"Mudaliar","year":"2013","journal-title":"Gastro-enterology"},{"key":"10.5604\/16652681.1226814_bib0170","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.cmet.2013.01.003","article-title":"Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist","volume":"17","author":"Sayin","year":"2013","journal-title":"Cell Metab"},{"key":"10.5604\/16652681.1226814_bib0175","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.cmet.2013.03.001","article-title":"The endocannabinoid system in energy homeostasis and the etiopathology of metabolic disorders","volume":"17","author":"Silvestri","year":"2013","journal-title":"Cell Metab"},{"key":"10.5604\/16652681.1226814_bib0180","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1038\/nm.3265","article-title":"Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocannabinoids mediates beta cell loss in type 2 diabetes","volume":"19","author":"Jourdan","year":"2013","journal-title":"Nat Med"},{"key":"10.5604\/16652681.1226814_bib0185","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1478-3231.2006.01401.x","article-title":"Endocannabinoid receptor CB2 in nonalcoholic fatty liver disease","volume":"27","author":"M\u00e9ndez-S\u00e1nchez","year":"2007","journal-title":"Liver Int"},{"key":"10.5604\/16652681.1226814_bib0190","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/hep.20733","article-title":"Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C","volume":"42","author":"He\u00b4zode","year":"2005","journal-title":"Hepatology"},{"key":"10.5604\/16652681.1226814_bib0195","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.22950","article-title":"Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis","volume":"50","author":"Karlmark","year":"2009","journal-title":"Hepatology"},{"key":"10.5604\/16652681.1226814_bib0200","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1111\/j.1530-0277.2009.00946.x","article-title":"Nitric oxide-mediated intestinal injury is required for alcohol-induced gut leakiness and liver damage","volume":"33","author":"Tang","year":"2009","journal-title":"Alcohol Clin Exp Res"},{"key":"10.5604\/16652681.1226814_bib0205","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jhep.2014.09.015","article-title":"Arginase 2 deficiency results in spontaneous steatohepatitis: a novel link between innate immune activation and hepatic de novo lipogenesis","volume":"62","author":"Navarro","year":"2015","journal-title":"J Hepatol"},{"key":"10.5604\/16652681.1226814_bib0210","doi-asserted-by":"crossref","first-page":"e0158156","DOI":"10.1371\/journal.pone.0158156","article-title":"Antifibrotic Effects of the Dual CCR2\/ CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney fibrosis","volume":"11","author":"Lefebvre","year":"2016","journal-title":"PLoS One"},{"key":"10.5604\/16652681.1226814_bib0215","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone. Vitamin E or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N Engl J Med"},{"key":"10.5604\/16652681.1226814_bib0220","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.jhep.2009.02.023","article-title":"Component of sylimarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells","volume":"50","author":"Trappoliere","year":"2009","journal-title":"J Hepatol"},{"key":"10.5604\/16652681.1226814_bib0225","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/S0002-9343(02)01244-5","article-title":"Milk thistle for the treatment of liver disease: a systematic review and meta-analysis","volume":"113","author":"Jacobs","year":"2002","journal-title":"Am J Med"},{"key":"10.5604\/16652681.1226814_bib0230","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00011-007-7153-8","article-title":"Protective effects of pir-fenidone on D-galactosamine and lipopolysaccharide-in-duced acute hepatotoxixity in rats","volume":"57","author":"Wang","year":"2008","journal-title":"Inflamm Res"},{"key":"10.5604\/16652681.1226814_bib0235","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jhep.2003.09.023","article-title":"Pirfenidone prevents endotoxin-in-duced liver injury after partial hepatectomy in rats","volume":"40","author":"Tsuchiya","year":"2004","journal-title":"J Hepatol"},{"key":"10.5604\/16652681.1226814_bib0240","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0168-8278(02)00272-6","article-title":"Pirfenidone effectively reverses experimental liver fibrosis","volume":"37","author":"Garc\u00eda","year":"2002","journal-title":"J Hepatol"},{"key":"10.5604\/16652681.1226814_bib0245","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.dld.2004.05.012","article-title":"The anti-fibrotic effects of pir-fenidone in rat liver fibrosis is mediated by downregulation of procollagen alpha 1(l), TIMP-1 and MMP2","volume":"36","author":"Di Sario","year":"2004","journal-title":"Dig Liver Dis"},{"key":"10.5604\/16652681.1226814_bib0250","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/1471-230X-14-131","article-title":"Treatment with pirfenidone for two years decreases fibrosis, cytokine levels and enhances CB2 gene expression in patients with chronic hepatitis C","volume":"14","author":"Flores-Contreras","year":"2014","journal-title":"BMC Gastroenterol"},{"key":"10.5604\/16652681.1226814_bib0255","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S1665-2681(19)30878-6","article-title":"Clinical decisions in hepatology: the pirfenidone case analysis","volume":"13","author":"Chavez-Tapia","year":"2014","journal-title":"Ann Hepatol"},{"key":"10.5604\/16652681.1226814_bib0260","first-page":"3213","article-title":"In liver fibrosis, dendritic cells govern hepatic inflammation in mice via TNF-alpha","volume":"119","author":"Connolly","year":"2009","journal-title":"J Clin Invest"},{"key":"10.5604\/16652681.1226814_bib0265","first-page":"768071","article-title":"The Role of Dendritic Cells in fi-brosis Progression in Nonalcoholic Fatty Liver Disease","volume":"2015","author":"Almeda-Valdes","year":"2015","journal-title":"Bi-omed Res Int"},{"key":"10.5604\/16652681.1226814_bib0270","first-page":"998","article-title":"Dendritic cells and liver fibrosis","volume":"1832","author":"Rahman","year":"2013","journal-title":"Bio-chim Biophys Acta"},{"key":"10.5604\/16652681.1226814_bib0275","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/hep.24621","article-title":"Dendritic cell regulation of carbon tetrachloride-induced murine liver fibrosis regression","volume":"55","author":"Jiao","year":"2012","journal-title":"Hepatology"},{"key":"10.5604\/16652681.1226814_bib0280","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1053\/j.gastro.2009.09.015","article-title":"Modulation of hepatic fibro-sis by c-Jun-N-terminal kinase inhibition","volume":"138","author":"Kluwe","year":"2010","journal-title":"Gastroenterology"},{"key":"10.5604\/16652681.1226814_bib0285","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1476-5381.2010.00815.x","article-title":"Aiming drug discovery at lysophosphatidic acid targets","volume":"161","author":"Tigyi","year":"2010","journal-title":"Br J Pharmacol"},{"key":"10.5604\/16652681.1226814_bib0290","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1126\/scitranslmed.3000111","article-title":"Serum amyloid P inhibits fibro-sis through Fc gamma R-dependent monocyte-macrophage regulation in vivo","volume":"1","author":"Casta\u00f1o","year":"2009","journal-title":"Sci Transl Med"},{"key":"10.5604\/16652681.1226814_bib0295","doi-asserted-by":"crossref","first-page":"e75361","DOI":"10.1371\/journal.pone.0075361","article-title":"Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioaceta-mide-induced liver disease","volume":"8","author":"Traber","year":"2013","journal-title":"PLoS One"},{"key":"10.5604\/16652681.1226814_bib0300","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0168-8278(01)00245-8","article-title":"Hepatocyte growth factor induces colla-genase (matrix metalloproteinase-1) via the transcription factor Ets-1 in human hepatic stellate cell line","volume":"36","author":"Ozaki","year":"2002","journal-title":"J Hepatol"},{"key":"10.5604\/16652681.1226814_bib0305","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/hep.510240328","article-title":"Antifibrogenic effect of a deletion variant of hepatocyte growth factor on liver fibrosis in rats","volume":"24","author":"Yasuda","year":"1996","journal-title":"Hepatology"},{"key":"10.5604\/16652681.1226814_bib0310","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/hep.20051","article-title":"Apoptosis: the nexus of liver injury and fibrosis","volume":"39","author":"Canbay","year":"2004","journal-title":"Hepatology"},{"key":"10.5604\/16652681.1226814_bib0315","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1124\/jpet.103.060129","article-title":"The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse","volume":"308","author":"Canbay","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.5604\/16652681.1226814_bib0320","doi-asserted-by":"crossref","first-page":"G642","DOI":"10.1152\/ajpgi.00037.2003","article-title":"Prolonged infusion of angiotensin II into normal rats induces stellate cell activation and proin-flammatory events in liver","volume":"285","author":"Bataller","year":"2003","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.5604\/16652681.1226814_bib0325","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.2174\/092986707782360169","article-title":"Renin-angiotensin system inhibitors as therapeutic alternatives in the treatment of chronic liver diseases","volume":"14","author":"Yoshiji","year":"2007","journal-title":"Curr Med Chem"},{"key":"10.5604\/16652681.1226814_bib0330","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/ncpgasthep0055","article-title":"Mechanisms of disease: mechanisms of hepatic fibrosis and therapeutic implications","volume":"1","author":"Friedman","year":"2004","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"key":"10.5604\/16652681.1226814_bib0335","doi-asserted-by":"crossref","first-page":"G113","DOI":"10.1152\/ajpgi.00200.2006","article-title":"Disruption of transforming growth factor-beta signaling by curcumin induces gene expression of per-oxisome proliferator-activated receptor-gamma in rat hepatic stellate cells","volume":"292","author":"Zheng","year":"2007","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.5604\/16652681.1226814_bib0340","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1002\/hep.21849","article-title":"Role of aVb6 integrin in acute biliary fibrosis","volume":"46","author":"Wang","year":"2007","journal-title":"Hepatology"},{"key":"10.5604\/16652681.1226814_bib0345","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1038\/nm.3282","article-title":"Targeting of av in-tegrin identifies a core molecular pathway that regulates fibrosis in several organs","volume":"19","author":"Henderson","year":"2013","journal-title":"Nat Med"},{"key":"10.5604\/16652681.1226814_bib0350","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1172\/JCI118925","article-title":"Endothelin antagonism in experimental hepatic fibrosis. Implications for endothelin in the pathogene-sis of wound healing","volume":"98","author":"Rockey","year":"1996","journal-title":"J Clin Invest"},{"key":"10.5604\/16652681.1226814_bib0355","first-page":"899","article-title":"Amelioration of liver fibrogenesis by dual inhibition of PDGF and TGF-beta with a combination of imatinib mesylate and ACE inhibitor in rats","volume":"17","author":"Yoshiji","year":"2006","journal-title":"Int J Mol Med"},{"key":"10.5604\/16652681.1226814_bib0360","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/labinvest.2010.148","article-title":"Hepatic and HSC-specific sor-afenib effects in rats with established secondary biliary cirrhosis","volume":"91","author":"Hennenberg","year":"2011","journal-title":"Lab Invest"},{"key":"10.5604\/16652681.1226814_bib0365","doi-asserted-by":"crossref","first-page":"G907","DOI":"10.1152\/ajpgi.00420.2004","article-title":"Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats","volume":"288","author":"Yoshiji","year":"2005","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.5604\/16652681.1226814_bib0370","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2005.06.015","article-title":"Oral imatinib treatment reduces early fibrogenesis but does not prevent progression in the long term","volume":"44","author":"Neef","year":"2006","journal-title":"J Hepatol"},{"key":"10.5604\/16652681.1226814_bib0375","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/hep.20425","article-title":"Antifibrotic effects of a tissue inhibitor of metalloproteinase-1 antibody on established liver fibrosis in rats","volume":"40","author":"Parsons","year":"2004","journal-title":"Hepatology"},{"key":"10.5604\/16652681.1226814_bib0380","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1053\/j.gastro.2003.12.045","article-title":"Treatment with human metalloprotein-ase-8 gene delivery ameliorates experimental rat liver cirrhosis","volume":"126","author":"Siller-L\u00f3pez","year":"2004","journal-title":"Gastroenterology"},{"key":"10.5604\/16652681.1226814_bib0385","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1053\/j.gastro.2012.06.036","article-title":"Deactivation of hepatic stellate cells during liver fibrosis resolution in mice","volume":"143","author":"Troeger","year":"2012","journal-title":"Gastroenterology"},{"key":"10.5604\/16652681.1226814_bib0390","doi-asserted-by":"crossref","first-page":"9448","DOI":"10.1073\/pnas.1201840109","article-title":"Myofibroblasts revert to an inactive pheno-type during regression of liver fibrosis","volume":"109","author":"Kisseleva","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.5604\/16652681.1226814_bib0395","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1053\/j.gastro.2009.04.033","article-title":"Unraveling the spider web of hepatic stellate cell apoptosis","volume":"136","author":"Pinzani","year":"2009","journal-title":"Gastroenterology"},{"key":"10.5604\/16652681.1226814_bib0400","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1023\/A:1024792529601","article-title":"Gli-otoxin ameliorates development of fibrosis and cirrhosis in a thioacetamide rat model","volume":"48","author":"Dekel","year":"2003","journal-title":"Dig Dis Sci"},{"key":"10.5604\/16652681.1226814_bib0405","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.jhep.2010.04.025","article-title":"Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells","volume":"53","author":"Trebicka","year":"2010","journal-title":"J Hepatol"}],"container-title":["Annals of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268119303606?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1665268119303606?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/publisherspanel.com\/icid\/pdf\/1226814","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T10:36:03Z","timestamp":1761647763000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1665268119303606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":81,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S1665268119303606"],"URL":"https:\/\/doi.org\/10.5604\/16652681.1226814","relation":{},"ISSN":["1665-2681"],"issn-type":[{"value":"1665-2681","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management Strategies for Liver Fibrosis","name":"articletitle","label":"Article Title"},{"value":"Annals of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.5604\/16652681.1226814","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2017 Fundaci\u00f3n Cl\u00ednica M\u00e9dica Sur, A.C. Published by Elsevier Espa\u00f1a, S.L.","name":"copyright","label":"Copyright"}]}}